Abiraterone acetate - Churchill Pharmaceuticals
Alternative Names: AAFP; Abiraterone acetate fine particle ; submicron abiraterone acetate; YONSA; YonsaLatest Information Update: 29 Jul 2022
At a glance
- Originator Churchill Pharmaceuticals
- Developer Churchill Pharmaceuticals; Institute of Cancer Research; Sun Pharmaceutical Industries
- Class Androstenols; Antiandrogens; Antineoplastics; Phenanthrenes; Pyridines; Small molecules
- Mechanism of Action CYP17A1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Prostate cancer
Most Recent Events
- 29 Jul 2022 Launched for Prostate cancer (Combination therapy, Hormone refractory, Metastatic disease) in USA (PO)
- 29 Mar 2022 Registered for Prostate cancer (Combination therapy, Late-stage disease, Metastatic disease, Hormone refractory) in Australia (PO)
- 29 Mar 2022 Registered for Prostate cancer (Combination therapy, Metastatic disease, Newly diagnosed) in Australia (PO)